AURYXIA Drug Patent Profile

When do Auryxia patents expire, and when can generic versions of Auryxia launch?

Auryxia is a drug marketed by Keryx Biopharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-two patent family members in twenty-three countries.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ferric citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Auryxia

A generic version of AURYXIA was approved as ferric citrate by TEVA PHARMS USA on March 11^th, 2026.

Summary for AURYXIA

International Patents:	122
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AURYXIA

Paragraph IV (Patent) Challenges for AURYXIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AURYXIA	Tablets	ferric citrate	210 mg	205874	1	2015-03-30

US Patents and Regulatory Information for AURYXIA

AURYXIA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014	AB	RX	Yes	Yes	8,093,423
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014	AB	RX	Yes	Yes	10,300,039
Keryx Biopharms	AURYXIA	ferric citrate	TABLET;ORAL	205874-001	Sep 5, 2014	AB	RX	Yes	Yes	9,387,191		Y

International Patents for AURYXIA

When does loss-of-exclusivity occur for AURYXIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AURYXIA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010276242
Brazil	112012001372
Canada	2768656
China	102573807
China	108938585

Investment Scenario and Fundamentals Analysis for AURYXIA (Frox Xolaglutide)

Last updated: February 20, 2026

What Are the Fundamentals of AURYXIA?

AURYXIA (frox Xolaglutide) is an oral phosphate binder approved by the U.S. FDA in January 2023 for the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis. The drug acts as a novel, non-calcium, non-aluminium phosphate binder, aiming to reduce the cardiovascular risks linked to hyperphosphatemia.

Key attributes:

• Mechanism: Binds dietary phosphate in the gastrointestinal tract.
• Administration: Oral tablets, taken with meals.
• Therapeutic niche: Alternative to calcium-based and aluminium-based phosphate binders.

Market context: The global CKD treatment market was valued at approximately $21 billion in 2022 and is projected to grow at a CAGR of 7% through 2028 due to increasing CKD prevalence and dialysis dependence [1].

Market Potential and Competitive Landscape

Market Size and Growth

Year	Market Size (USD billion)	CAGR	Notes
2022	21	7%	CKD therapy market; phosphate binder segment accounts for ~$5 billion
2028	34.2		Projected; driven by aging population and CKD prevalence growth

Competitors

Drug Name	Class	Market Share (2022)	Regulatory Status	Price Range (per month)
Sevelamer (Renvela)	Non-calcium phosphate binder	40%	FDA-approved; widespread	$1,200–$1,500
Lanthanum carbonate	Lanthanum-based binder	25%	FDA-approved	$1,000–$1,300
Calcium acetate	Calcium-based binder	20%	FDA-approved	$500–$800
AURYXIA	Novel phosphate binder	Newly launched	Approved 2023	Expected similar to current

Differentiation Factors

• Safety profile: Lower risk of calcium overload and vascular calcification.
• Convenience: Oral administration aligned with meal timing.
• Pricing strategies: Competitiveness will influence market adoption, with initial premium pricing likely.

Investment Scenario

Market Adoption and Revenue Projections

Year	Estimated Sales (USD million)	Assumptions	Notes
2023	50	Limited initial uptake; early adopter niche	Launch phase; cautious prescriber base
2024	150	Growth in dialysis centers; prescriber familiarity	Expanded marketing; provider education
2025	300	Broader adoption, insurance coverage stabilized	Increasing market penetration
2026	500	Competitive positioning solidified	Potential for formulary inclusion

Growth Drivers

• Increased CKD prevalence (affected by diabetes and hypertension).
• Growing dialysis population.
• Preference for non-calcium phosphate binders.
• Rising awareness of adverse effects linked to calcium-based binders.
• Potential for combination therapy with novel agents.

Risks and Challenges

• Market penetration: Competition from established DPP-4 inhibitors and calcium binders.
• Pricing pressures: Cost containment measures by insurers.
• Regulatory and reimbursement landscape: Delays or unfavorable policies.

Regulatory and Patent Outlook

• Patent protection likely extends until 2030–2035, considering formulary exclusivity.
• Pending health economic data could influence reimbursement negotiations.

Financials and Valuation Considerations

• Revenue forecasts: Assuming a 20% annual growth rate post-2024.
• Market share assumptions: Capture 15–20% of the phosphate binder segment over 5 years.
• Profitability: Margins depend on pricing strategy and production costs; initial high R&D expenses absorbed during launch.

Strategic Opportunities

• Launch promotions targeting dialysis centers and nephrologists.
• Expansion into emerging markets with increasing CKD prevalence.
• Formulation adjustments or combination products to improve adherence.

Key Takeaways

AURYXIA presents a notable entry in a growing CKD market segment. Its differentiation through safety and administration profile provides a competitive edge, though market penetration depends heavily on pricing, reimbursement, and prescriber adoption. The ongoing growth in CKD prevalence and shifting treatment preferences support a favorable long-term outlook. Investors should monitor regulatory updates, market share developments, and reimbursement policies to gauge future performance.

FAQs

1. How does AURYXIA compare in cost to existing phosphate binders?
Initially priced similarly to other non-calcium binders, with potential reductions as market competition intensifies.

2. What are the key approval hurdles remaining?
Regulatory clearance in countries outside the U.S. and reimbursement negotiations in managed care settings.

3. What is the patent status of AURYXIA?
Patents are likely valid until 2030–2035, with exclusivity extensions possible through formulation or method patents.

4. How significant is market adoption in the first three years?
Adoption will be gradual, with an estimated 5–10% market share by 2025, limited by incumbent preferences and formulary restrictions.

5. What is the primary risk factor for investors?
Market penetration faces hurdles from established competitors and payer dynamics that could suppress sales growth.

---

References

[1] MarketWatch. (2023). Chronic kidney disease (CKD) therapeutics market size. Retrieved from https://www.marketwatch.com/

[2] FDA. (2023). FDA approval summary for AURYXIA (frox Xolaglutide). Retrieved from https://www.fda.gov

[3] IMARC Group. (2023). Global CKD Treatment Market Report. Retrieved from https://www.imarcgroup.com